NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $41 PT on Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR)
Aegis Capital Corp. has reiterated a ‘Buy’ rating and $41 price target on the stock of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR). The report follows the company’s recent presentation of encouraging data for eptinezumab (formerly ALD403) at the 69th Annual American Academy of Neurology (AAN) meeting. Eptinezumab is currently in phase 3 clinical development for the prevention of chronic migraines. The Aegis analyst noted that this data suggests that increases in responder rates and reductions in HIT-6 scores for eptinezumab resulted in improved quality of life for those with chronic migraines. Additional data is expected to be released in the second…







